In another study using similar plasma cutoffs, a low baseline concentration of plasma IL-6 (< 11.150 pg/ml) associated with longer PFS (p = 0.0142) following anti-PD-1 therapies in stage III-IV patients with NSCLC [29]. Here, IL6 is linked to non-small cell lung carcinoma.